Amgen Competitors and Similar CompaniesClear all
Abbott's competitors and similar companies include PRA Health Sciences, Viatris, Allergan, Novo Nordisk, AstraZeneca, Biogen, Avantor, Hospira, AbbVie, Coherus Oncology and Galenica.
 Abbott Abbott Laboratories is a company that specializes in the discovery, development, manufacture, and sale of healthcare products. |  PRA Health Sciences PRA Health Sciences is a contract research organization that provides outsourced clinical development services to the biotechnology and pharmaceutical industries. |  Viatris Viatris is a pharmaceutical company that develops and manufactures branded and generic medicines, biosimilar medicines, and over-the-counter products. |  Allergan Allergan is a healthcare company focused on developing, manufacturing, and commercializing branded pharmaceutical, device, biologic, surgical, and regenerative medicine products. |  Novo Nordisk Novo Nordisk is a healthcare company that designs and manufactures pharmaceutical products. |  AstraZeneca AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. |  Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. |  AbbVie AbbVie is a pharmaceutical company engaged in the research, development, manufacturing, commercialization, and sale of medicines and therapies. |  Coherus Oncology Coherus BioSciences is a biopharmaceutical company that focuses on the research, development, and commercialization of cancer treatments. |  Galenica Galenica is a provider of healthcare services and products operating in two business segments: Products & Care, Logistics & IT. | |||
Founding Date | Founding Date 1888 | Founding Date 1976 | Founding Date 2020 | Founding Date 1948 | Founding Date 1923 | Founding Date 1999 | Founding Date 1978 | Founding Date 1904 | Founding Date 2004 | Founding Date 2013 | Founding Date 2010 | Founding Date 1927 |
Type | Type Public | Type Subsidiary | Type Public | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Subsidiary | Type Public | Type Public | Type Public |
Tags | ||||||||||||
Locations | Locations Abbott Park, US HQ Tiranë, AL Buenos Aires, AR Yerevan, AM Doncaster, AU East Brisbane, AU Macquarie Park, AU see more | Locations Raleigh, US HQ Buenos Aires, AR Haymarket, AU South Yarra, AU Minsk, BY Mechelen, BE São Paulo, BR see more | Locations Canonsburg, US HQ Carole Park, AU Millers Point, AU Campos Dos Goytacazes, BR São Paulo, BR Sofia, BG Toronto, CA see more | Locations Dublin, IE HQ Buenos Aires, AR Roseville, AU Machelen, BE Guarulhos, BR Las Condes, CL Bogotá, CO see more | Locations Bagsværd, DK HQ Tirana, AL Boufarik, DZ Hydra, DZ Tizi Ouzou, DZ Buenos Aires, AR North Sydney, AU see more | Locations Cambridge, GB HQ Alger, DZ Buenos Aires, AR Macquarie Park, AU Macquarie Park, AU North Ryde, AU Wien, AT see more | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more | Locations Radnor, US HQ Lutterworth, GB Allentown, US | Locations Lake Forest, US HQ | Locations North Chicago, US HQ Hydra, DZ Buenos Aires, AR Mascot, AU Wien, AT Wavre, BE Sarajevo, BA see more | Locations Redwood City, US HQ Camarillo, US | Locations Bern, CH HQ |
Employees | Employees 114,000 | Employees 18,1003% increase | Employees 38,0003% increase | Employees 10,5471% decrease | Employees 77,406 | Employees 94,300 | Employees 7,605 | Employees 13,500 | Employees 4,23819% decrease | Employees 55,00010% increase | Employees 14736% decrease | Employees 4,5111% increase |
Valuation ($) | Valuation ($) 196.1 b | Valuation ($) N/A | Valuation ($) 14 b | Valuation ($) N/A | Valuation ($) 599.3 b | Valuation ($) 2.7 b | Valuation ($) 26.7 b | Valuation ($) 15.3 b | Valuation ($) N/A | Valuation ($) 335 b | Valuation ($) 85.6 m | Valuation ($) N/A |
Financial | ||||||||||||
Revenue (est.) | Revenue (est.) $44.3b (FY, 2025) | Revenue (est.) $3.2b (FY, 2020) | Revenue (est.) $14.3b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) kr309.1b (FY, 2025) | Revenue (est.) $58.7b (FY, 2025) | Revenue (est.) $9.9b (FY, 2025) | Revenue (est.) $6.6b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $61.2b (FY, 2025) | Revenue (est.) $42.2m (FY, 2025) | Revenue (est.) CHF4.1b (FY, 2025) |
Cost of goods | Cost of goods $19.3b (FY, 2025) | Cost of goods $2.3b (FY, 2020) | Cost of goods $9.3b (FY, 2025) | Cost of goods N/A | Cost of goods kr46.1b (FY, 2025) | Cost of goods $4.9b (FY, 2025) | Cost of goods $2.4b (FY, 2025) | Cost of goods $4.4b (FY, 2025) | Cost of goods N/A | Cost of goods $18.2b (FY, 2025) | Cost of goods $13.8m (FY, 2025) | Cost of goods CHF3b (FY, 2025) |
Gross profit | Gross profit $25b (FY, 2025) | Gross profit $868.6m (FY, 2020) | Gross profit $5b (FY, 2025) | Gross profit N/A | Gross profit kr263b (FY, 2025) | Gross profit $54.2b (FY, 2025) | Gross profit $7.5b (FY, 2025) | Gross profit $2.1b (FY, 2025) | Gross profit N/A | Gross profit $43b (FY, 2025) | Gross profit $28.4m (FY, 2025) | Gross profit CHF1.1b (FY, 2025) |
Net income | Net income $6.5b (FY, 2025) | Net income $197m (FY, 2020) | Net income ($3.5b) (FY, 2025) | Net income N/A | Net income kr102.4b (FY, 2025) | Net income $10.2b (FY, 2025) | Net income $1.3b (FY, 2025) | Net income ($503.2m) (FY, 2025) | Net income N/A | Net income $4.2b (FY, 2025) | Net income $168m (FY, 2025) | Net income CHF183.9m (FY, 2025) |
Operating ⚠ | ||||||||||||
Countries | Countries N/A | Countries N/A | Countries 165 (Q1, 2023) | Countries 100 (Q1, 2020) | Countries N/A | Countries 130 (FY, 2021) | Countries N/A | Countries 180 (FY, 2023) | Countries N/A | Countries 70 (FY, 2022) | Countries N/A | Countries N/A |
Facilities | Facilities N/A | Facilities N/A | Facilities N/A | Facilities 21 (FY, 2019) | Facilities N/A | Facilities N/A | Facilities N/A | Facilities 200 (FY, 2023) | Facilities N/A | Facilities N/A | Facilities N/A | Facilities N/A |
Manufacturing Facilities | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 13 (FY, 2019) | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 45 (FY, 2023) | Manufacturing Facilities N/A | Manufacturing Facilities 19 (FY, 2022) | Manufacturing Facilities N/A | Manufacturing Facilities N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 6 (FY, 2024) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 1 (FY, 2020) | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2024) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 1 (FY, 2020) | Phase III Trials Products N/A |
Product Categories | Product Categories N/A | Product Categories N/A | Product Categories 3 (Q1, 2023) | Product Categories N/A | Product Categories N/A | Product Categories N/A | Product Categories N/A | Product Categories N/A | Product Categories N/A | Product Categories 6 (FY, 2022) | Product Categories N/A | Product Categories N/A |
Projects in R&D Pipeline | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 177 (FY, 2021) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 6 (FY, 2020) | Projects in R&D Pipeline N/A |
Funding | ||||||||||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 1b | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 3.8b | Total funding raised $ 174.5m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
PRA Health Sciences
HQ
Raleigh, US
PRA Health Sciences is a contract research organization that provides outsourced clinical development services to the biotechnology and pharmaceutical industries.
View companyViatris
HQ
Canonsburg, US
Employees
38,000↑ 3% increase
Viatris is a pharmaceutical company that develops and manufactures branded and generic medicines, biosimilar medicines, and over-the-counter products.
View companyAllergan
HQ
Dublin, IE
Allergan is a healthcare company focused on developing, manufacturing, and commercializing branded pharmaceutical, device, biologic, surgical, and regenerative medicine products.
View companyNovo Nordisk
HQ
Bagsværd, DK
Employees
77,406
Novo Nordisk is a healthcare company that designs and manufactures pharmaceutical products.
View company